The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Natera, Inc. (“Natera” or “the Company”) (NASDAQ: NTRA) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The New York Times published an article on January 1, 2022, questioning the accuracy of certain non-invasive prenatal tests (“NIPT”), including Natera’s NIPT, Panorama. The Times article claims that 85% of such tests are incorrect. Based on this news, shares of Natera fell sharply. The Campaign for Accountability then filed a complaint with the SEC on January 14, 2022, claiming that the Company misled investors about false positives and other problems with its tests. Based on this news, the Company’s stock once again dropped sharply.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005899/en/